Fenwick Represents Playground Global in IP Due Diligence of Amber Bio's $26 Million Seed Financing

Fenwick represented Playground Global, a venture capital firm based in Palo Alto, CA, in the intellectual property due diligence aspect of its seed financing investment in Amber Bio, a biotechnology company pioneering multi-kilobase gene editing platforms to reach previously undruggable diseases. Playground Global and Andreessen Horowitz Bio + Health led the financing with participation from Eli Lilly, RDF (Retinal Degeneration Fund), Hummingbird Ventures, and Pillar VC.

The funding will be used to advance a first-of-its-kind RNA editing platform which enables multi-kilobase edits, allowing a single drug to treat diseases with high allelic diversity. More information about Amber Bio’s $26 million seed financing can be obtained from the company’s press release.

The Fenwick transaction team was led by intellectual property partner Key Shin, counsel Amy Klann and associate Lucas Greder.


Don’t have an account yet?